Mirum Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	302.84	286.33	128	131.34	142.09	11.97
Short-Term Investments	0	0	123.72	125.2	89.73	104.69
Cash & Cash Equivalents	302.84	286.33	251.72	256.54	231.82	116.66
Cash Growth	30.49%	13.75%	-1.88%	10.66%	98.71%	-
Receivables	55	67.97	23.99	3.27	0	0
Inventory	21.61	22.31	5.57	1.51	0	0
Other Current Assets	10.02	10.94	-91.05	-94.73	4.53	2.7
Total Current Assets	389.47	387.54	190.23	166.59	236.35	119.36
Property, Plant & Equipment	1.18	1.99	2.35	2.55	3.24	3.73
Long-Term Investments	0	0	0	4.98	0	23.29
Goodwill and Intangibles	257.44	252.93	58.95	18.74	0	0
Other Long-Term Assets	3.87	4.17	101.38	101.79	1.27	0.32
Total Long-Term Assets	262.5	259.08	162.68	128.06	4.51	27.35
Total Assets	651.96	646.62	352.91	294.65	240.86	146.71
Accounts Payable	15.98	7.42	8.69	9.17	3.15	3.35
Current Debt	0.36	1.1	0.93	0.71	0.64	0.4
Other Current Liabilities	89.57	78.54	55.11	32.72	14.68	9.33
Total Current Liabilities	105.91	87.06	64.73	42.6	18.46	13.08
Long-Term Debt	307.16	307.04	141.61	131.83	50.28	3.25
Other Long-Term Liabilities	4.29	3.85	4.53	0.02	0.03	0.04
Total Long-Term Liabilities	311.45	310.89	146.14	131.84	50.31	3.29
Total Liabilities	417.36	397.95	210.87	174.44	68.77	16.36
Total Debt	307.52	308.14	142.54	132.54	50.91	3.65
Debt Growth	114.03%	116.18%	7.55%	160.32%	1295.67%	-
Retained Earnings	-581.52	-556.24	-392.82	-257.16	-173.17	-69.9
Comprehensive Income	-0.01	1.64	-0.22	-0.04	0.08	0.13
Shareholders' Equity	234.6	248.67	142.04	120.21	172.1	130.35
Net Cash / Debt	-4.68	-21.82	109.18	124	180.91	113.01
Net Cash / Debt Growth	-	-	-11.95%	-31.45%	60.08%	-
Net Cash Per Share	-0.10	-0.53	3.21	4.09	7.16	9.84
Working Capital	283.56	300.48	125.5	124	217.89	106.29
Book Value Per Share	5.00	6.08	4.20	3.96	6.82	11.35

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).